

# YaleNewHaven**Health**

## **Smilow Cancer Hospital**

333 Cedar Street  
PO Box 208058  
New Haven, CT 06520-8058

Yale CANCER  
CENTER  
A Comprehensive Cancer Center Designated  
by the National Cancer Institute

NON-PROFIT ORG.  
U.S. POSTAGE  
**PAID**  
NEW HAVEN, CT  
PERMIT #526

**Hematology Program**  
**Smilow Cancer Hospital**  
**at New Haven**  
35 Park Street  
New Haven, CT 06511  
203-200-4363  
**[smilowcancerhospital.org](http://smilowcancerhospital.org)**

# Hematologist, Dr. Maximilian Stahl, Joins Smilow Cancer Hospital



## Maximilian Stahl, MD

*Director, Leukemia Program*

*Assistant Professor of Medicine*

*(Medical Oncology and Hematology)*

Appointments:

203-200-4363

Email:

[maximilian.stahl@yale.edu](mailto:maximilian.stahl@yale.edu)

## Location:

Smilow Cancer Hospital

at New Haven

35 Park Street

New Haven, CT 06511

Maximilian Stahl, MD, is the Director of the Leukemia Program and an Assistant Professor of Medicine (Medical Oncology and Hematology). He cares for patients with hematologic malignancies at Smilow Cancer Hospital in New Haven with a particular focus on acute and chronic leukemias and myelodysplastic syndromes. Dr. Stahl joins Yale from Dana Farber Cancer Institute and Harvard Medical School where he was an Assistant Professor of Medicine within their Adult Leukemia Program.

Dr. Stahl received his medical degree from Hannover Medical School in Hannover, Germany and completed residency training at Yale School of Medicine where he

also served as chief medical resident. He then completed a fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center. His clinical research evaluates outcomes achieved with novel therapeutic approaches for AML, MDS, and MPNs, with a focus on identifying molecular predictors of these outcomes. Dr. Stahl actively leads translational research with the goal of bringing basic scientific discoveries from the lab to the clinic to benefit patients with leukemia. Towards this goal, he conducts early phase clinical trials testing novel treatment approaches.